Land: Kanada
Sprache: Englisch
Quelle: Health Canada
FIBRINOGEN (HUMAN); THROMBIN (HUMAN)
OMRIX BIOPHARMACEUTICALS LTD
B02BC30
COMBINATIONS
90MG; 1200UNIT
SOLUTION
FIBRINOGEN (HUMAN) 90MG; THROMBIN (HUMAN) 1200UNIT
TOPICAL
2X1ML/2X2ML/2X5ML
Schedule D
HEMOSTATICS
Active ingredient group (AIG) number: 0252708001; AHFS:
CANCELLED POST MARKET
2023-06-06
1 PRODUCT MONOGRAPH EVICEL ® 2 x 1 mL, 2 x 2 mL & 2 x 5 mL Kits Fibrin Sealant Kit Ph. Eur. Haemostatic Agent COMPONENT HUMAN CLOTTABLE PROTEIN: HUMAN THROMBIN: STRENGTH FACTOR XIII 50- 90 mg/mL 2-15 IU/mL 800-1200 IU/mL DOSAGE FORM Single use kits consisting of one vial each of frozen sterile solutions of Human Clottable Protein and Thrombin EVICEL ® is a registered trademark of Johnson & Johnson. Sponsor Name: Omrix Biopharmaceuticals Ltd. Sponsor Address: MDA Blood Bank, Sheba Hospital, Ramat-Gan POB 888, Kiryat Ono 5510801 ISRAEL Importer/Distributor: Johnson & Johnson Medical Products 200 Whitehall Drive Markham, Ontario L3R 0T5 CANADA Submission Control No: 208336 Date of Approval: October 13, 2017 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................ 3 SUMMARY PRODUCT INFORMATION ............................................................... 3 DESCRIPTION .......................................................................................................... 3 INDICATIONS AND CLINICAL USE..................................................................... 5 CONTRAINDICATIONS .......................................................................................... 6 WARNINGS AND PRECAUTIONS ........................................................................ 6 ADVERSE REACTIONS .......................................................................................... 9 DRUG INTERACTIONS ......................................................................................... 13 DOSAGE AND ADMINISTRATION ..................................................................... 13 OVERDOSAGE ....................................................................................................... 17 ACTION AND CLINICAL PHARMACOLOGY ................................................... 17 STORAGE AND STABILITY ................................................................................ 17 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................. Lesen Sie das vollständige Dokument